Artikel
Galectin-1 expression in human glioblastoma specimens compared to normal human brain tissue and human astrocytes
Galectin-1 expression in humanen Glioblastomproben im Vergleich zu Normalhirngewebe und humanen Astrozyten
Suche in Medline nach
Autoren
-
Hanna Goett
- Justus-Liebig-Universität Gießen, Klinik für Neurochirurgie, Gießen, Deutschland
-
Christian Koch
- Justus-Liebig-Universität Gießen, Klinik für Anästhesie, Gießen, Deutschland
-
Anne Schänzer
- Justus-Liebig-Universität, Institut für Neuropathologie, Gießen, Deutschland
-
Malgorzata Kolodziej
- Justus-Liebig-Universität Gießen, Klinik für Neurochirurgie, Gießen, Deutschland
-
Frank Patrick Schwarm
- Justus-Liebig-Universität Gießen, Klinik für Neurochirurgie, Gießen, Deutschland
-
Eberhard Uhl
- Justus-Liebig-Universität Gießen, Klinik für Neurochirurgie, Gießen, Deutschland
-
Marco Stein
- Justus-Liebig-Universität, Neurochirurgie, Gießen, Deutschland
| Veröffentlicht: | 8. Mai 2019 |
|---|
Gliederung
Text
Objective: Galectin-1 (Gal-1) is involved in tumor development, and in tumor progression. In this study we investigated Gal-1 expression in human methylated and unmethylated GBM specimens compared to normal brain tissue (NBT), and human cultured astrocytes (HCA). In a second step the influence of Gal-1 overexpression on overall survival (OS) and progression-free survival (PFS) was studied.
Methods: In 33 specimens of GBM patients, 4 NBT specimens, and HCA Gal-1 expression was determined by quantitative real-time polymerase chain reaction (qPCR) and immunohistochemistry (IHC) using a dimensionless semiquantitative immunoreactivity score (IRS). Gal-1 expression by qPCR below the mean was defined as low Gal-1 expression (LGE) in GBM specimens. Gal-1 expression above the mean was defined as high Gal-1 expression (HGE). The influence of Gal-1 expression in qPCR and IHC on PFS and OS was analyzed by the Kaplan-Meier method. Cox regression analysis was used to calculate the hazard ratio (HR) and 95% confidence interval (CI).
Results: Mean Gal-1 expression by qPCR was significantly higher in GBM specimens (5.36±6.4) compared to NBT [0.34±0.23 (P=0.018)], and to HCA [1.07±0.43 (P=0.033)].. Median age was 58 (IQR: 52–67) years. Median overall survival (OS) was 16 (IQR: 13–19) month and median PFS was 6 (IQR: 4–9) months. Patients with HGE on mRNA level had a shorter median PFS than patients with LGE [4 (3–5.5) vs. 7 (6–9) month, HR: 2.75, 95% CI: 1.26–5.99, P=0.017]. Median OS was not significantly shorter in patients with HGE compared to patients with LGE [14 (11.5–20) vs.16 (14–18.75) months, HR: 1.21, 95% CI: 0.54–2.71, P=0.645]. Mean Gal-1 expression on protein level was 13.1±7.9 (IRS) in the GBM specimens. Patients with an IRS above the mean had lower median PFS [4 (3.25–5.75) vs. 8 (6–9) months [HR: 5.73, 95% CI: 2.11–15.6, P=0.01)]. No differences for median OS between high and low IRS was observed [16 (12.25–18.75) vs. 16 (14.5–20.0) month, HR: 1.44, 95% CI: 0.63–3.26), P=0.387)]. In 19 patients (57.6%) MGMT promotor was methylated, in 14 patients (42.4%) unmethylated. Methylated patients had a slightly higher mean IRS 13.08±6.76 compared to unmethylated patients (11.63±8.57, P=0.627).
Conclusion: Gal-1 is overexpressed on mRNA and protein level in human GBM specimens compared to NBT and HCA. Gal-1 overexpression seems to be associated with a shorter PFS in patients with GBM, independent of MGMT methylation status. Gal-1 could be a promising target of anticancer therapies in human GBM.
